INNOVENT'S PARTNER OLLIN BIOSCIENCES ANNOUNCES FINAL DATA FROM RANDOMIZED HEAD-TO-HEAD STUDY OF IBI324 COMPARED TO FARICIMAB (VABYSMO) IN WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA

Reuters · 03/31 00:00

Please log in to view news